Rheumatoid Arthritis
Conditions
Keywords
Safety, Long-term observation, Routine Clinical Setting, Rheumatoid Arthritis, Effectiveness
Brief summary
Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over 2 years.
Detailed description
Patients with rheumatoid arthritis who started treatment with adalimumab in a normal clinical setting according to the product label were documented. The follow-up observation period was for 2 years and focused on safety information and maintenance of efficacy during a normal clinical setting. Follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Moderate to severe active rheumatoid arthritis in adults with insufficient response to disease-modifying antirheumatic drugs, including methotrexate * Moderate to severe active rheumatoid arthritis in adults who have not been treated with methotrexate before. In case of incompatibility with methotrexate, Humira can be used as monotherapy
Exclusion criteria
* Hypersensitivity against the drug or one of the other ingredients * Active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) * Moderate to severe cardiac insufficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Disease Activity Score (DAS) 28 | Baseline and Months 3, 6, 9, 12, 18, and 24 | The Disease Activity Score 28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 score. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. |
| Percentage of Participants in DAS28 Remission | Months 3, 6, 9, 12, 18, and 24 | Clinical remission is defined as a disease activity score (DAS) 28 score of \< 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Erythrocyte Sedimentation Rate (ESR) Over Time | Baseline and Months 3, 6, 9, 12, 18, and 24 | Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. |
| C-Reactive Protein (CRP) Levels Over Time | Baseline and Months 3, 6, 9, 12, 18, and 24 | C-Reactive Protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. |
| Tender Joint Count (TJC) Over Time | Baseline and Months 3, 6, 9, 12, 18, and 24 | Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. |
| Swollen Joint Count (SJC) Over Time | Baseline and Months 3, 6, 9, 12, 18, and 24 | Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. |
| Hannover Functional Questionnaire (FFbH) Over Time | Baseline and Months 3, 6, 9, 12, 18, and 24 | A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score. The FFbH was calculated from this patient score by the following formula: FFbH = (patient score x 100) ÷ 2 (number of valid responses). The resulting FFbH score reflects the degree of remaining functional capacity where 0 indicates maximal impairment and 100 indicates maximal functional capacity. |
| Patients Global Assessment of Disease Activity Over Time | Baseline and Months 3, 6, 9, 12, 18 and 24 | Participants indicated their global assessment of disease activity over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. |
| Percentage of Participants With a Significant Therapeutic Response | Baseline and Months 3, 6, 9, 12, 18, and 24 | Significant therapeutic response was determined by DAS28 critical difference (Dcrit). A Dcrit response is a statistically determined value that exceeds the threshold of random fluctuation and signifies a positive individual response during treatment. A DAS28-Dcrit individual therapeutic response is defined as a decrease (improvement) in DAS28 from Baseline of ≥ 1.8. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. |
| Participants Assessment of Pain Over Time | Baseline and Months 3, 6, 9, 12, 18, and 24 | Participants indicated their level of pain over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. |
| Percentage of Participants With Impairment in Daily Activities | Baseline and Months 3, 6, 9, 18, and 24 | Participants were asked to report how many days of impairment in daily activities they had experienced in the last 4 weeks. |
| Number of Days Missed From Work Due to Rheumatoid Arthritis | Baseline and Months 6, 12, 18, and 24 | Participants reported the number of days they had missed from work in the prior 6 months. The Baseline measurement includes data for the prior 12 months. |
| Percentage of Participants With In-patient Hospitalization | Month 6, 12, 18, and 24 | The percentage of participants with in-patient hospitalization in the prior 6 months. Baseline data includes in-patient hospitalizations that occurred within the prior 12 months. |
| Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Baseline and Months 3, 6, 9, 12, 18, and 24 | — |
| Participants Assessment of Fatigue Over Time | Baseline and Month 3, 6, 9, 12, 18, and 24 | Participants indicated their level of fatigue over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. |
| Percentage of Participants With Low, Moderate and High Disease Activity | Baseline and Months 3, 6, 9, 12, 18, and 24 | The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Low disease activity is defined as a DAS28 score ≤ 3.2; Moderate disease activity as a DAS28 \>3.2 to ≤5.1; High disease activity as a DAS28 \>5.1. |
Countries
Germany
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Rheumatoid Arthritis Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed for up to 24 months. | 4,208 |
| Total | 4,208 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse drug reaction | 218 |
| Overall Study | Clinical remission | 37 |
| Overall Study | Lack of Efficacy | 663 |
| Overall Study | Lost to Follow-up | 1,390 |
| Overall Study | Other reasons | 260 |
Baseline characteristics
| Characteristic | Rheumatoid Arthritis |
|---|---|
| Age, Continuous | 54.6 years STANDARD_DEVIATION 13.2 |
| Gender Female | 3199 participants |
| Gender Male | 958 participants |
| Region of Enrollment Germany | 4208 participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 4,208 |
| serious Total, serious adverse events | 245 / 4,208 |
Outcome results
Change From Baseline in Disease Activity Score (DAS) 28
The Disease Activity Score 28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 score. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set (FAS). Participants with inadequate data or who met other exclusion criteria were not included in the FAS. n indicates the number of participants with available data at each time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Change From Baseline in Disease Activity Score (DAS) 28 | Month 3 (n=2620) | -1.5 units on a scale | Standard Deviation 1.3 |
| Rheumatoid Arthritis | Change From Baseline in Disease Activity Score (DAS) 28 | Month 6 (n=2243 | -1.8 units on a scale | Standard Deviation 1.4 |
| Rheumatoid Arthritis | Change From Baseline in Disease Activity Score (DAS) 28 | Month 9 (n=1877) | -1.9 units on a scale | Standard Deviation 1.4 |
| Rheumatoid Arthritis | Change From Baseline in Disease Activity Score (DAS) 28 | Month 12 (n=1776) | -2.0 units on a scale | Standard Deviation 1.4 |
| Rheumatoid Arthritis | Change From Baseline in Disease Activity Score (DAS) 28 | Month 18 (n=1519) | -2.1 units on a scale | Standard Deviation 1.4 |
| Rheumatoid Arthritis | Change From Baseline in Disease Activity Score (DAS) 28 | Month 24 (n=1248) | -2.2 units on a scale | Standard Deviation 1.4 |
Percentage of Participants in DAS28 Remission
Clinical remission is defined as a disease activity score (DAS) 28 score of \< 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity.
Time frame: Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rheumatoid Arthritis | Percentage of Participants in DAS28 Remission | Month 3 (n=2620) | 18.1 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants in DAS28 Remission | Month 6 (n=2243) | 22.0 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants in DAS28 Remission | Month 12 (n=1776) | 27.2 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants in DAS28 Remission | Month 18 (n=1519) | 29.8 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants in DAS28 Remission | Month 24 (n=1248) | 34.6 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants in DAS28 Remission | Month 9 (n=1877) | 26.1 percentage of participants |
C-Reactive Protein (CRP) Levels Over Time
C-Reactive Protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | C-Reactive Protein (CRP) Levels Over Time | Month 0 (n=2899) | 20.0 mg/L | Standard Deviation 36.6 |
| Rheumatoid Arthritis | C-Reactive Protein (CRP) Levels Over Time | Month 3 (n=2677) | 11.9 mg/L | Standard Deviation 31.9 |
| Rheumatoid Arthritis | C-Reactive Protein (CRP) Levels Over Time | Month 6 (n=2289) | 9.2 mg/L | Standard Deviation 19.5 |
| Rheumatoid Arthritis | C-Reactive Protein (CRP) Levels Over Time | Month 9 (n=1936) | 8.1 mg/L | Standard Deviation 15.8 |
| Rheumatoid Arthritis | C-Reactive Protein (CRP) Levels Over Time | Month 12 (n=1813) | 8.0 mg/L | Standard Deviation 17.7 |
| Rheumatoid Arthritis | C-Reactive Protein (CRP) Levels Over Time | Month 18 (n=1537) | 6.6 mg/L | Standard Deviation 11.9 |
| Rheumatoid Arthritis | C-Reactive Protein (CRP) Levels Over Time | Month 24 (n=1297) | 5.7 mg/L | Standard Deviation 10.9 |
Erythrocyte Sedimentation Rate (ESR) Over Time
Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Erythrocyte Sedimentation Rate (ESR) Over Time | Month 0 (n=2900) | 32.1 mm/hour | Standard Deviation 22 |
| Rheumatoid Arthritis | Erythrocyte Sedimentation Rate (ESR) Over Time | Month 3 (n=2684) | 23.2 mm/hour | Standard Deviation 20.2 |
| Rheumatoid Arthritis | Erythrocyte Sedimentation Rate (ESR) Over Time | Month 6 (n=2259) | 22.1 mm/hour | Standard Deviation 19.1 |
| Rheumatoid Arthritis | Erythrocyte Sedimentation Rate (ESR) Over Time | Month 9 (n=1910) | 21.6 mm/hour | Standard Deviation 18.2 |
| Rheumatoid Arthritis | Erythrocyte Sedimentation Rate (ESR) Over Time | Month 12 (n=1805) | 21.4 mm/hour | Standard Deviation 17.9 |
| Rheumatoid Arthritis | Erythrocyte Sedimentation Rate (ESR) Over Time | Month 18 (n=1515) | 21.0 mm/hour | Standard Deviation 17.5 |
| Rheumatoid Arthritis | Erythrocyte Sedimentation Rate (ESR) Over Time | Month 24 (n=1263) | 21.2 mm/hour | Standard Deviation 18.7 |
Hannover Functional Questionnaire (FFbH) Over Time
A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score. The FFbH was calculated from this patient score by the following formula: FFbH = (patient score x 100) ÷ 2 (number of valid responses). The resulting FFbH score reflects the degree of remaining functional capacity where 0 indicates maximal impairment and 100 indicates maximal functional capacity.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Hannover Functional Questionnaire (FFbH) Over Time | Month 0 (n=2938) | 61.9 units on a scale | Standard Deviation 22.4 |
| Rheumatoid Arthritis | Hannover Functional Questionnaire (FFbH) Over Time | Month 3 (n=2755) | 68.4 units on a scale | Standard Deviation 22.5 |
| Rheumatoid Arthritis | Hannover Functional Questionnaire (FFbH) Over Time | Month 6 (n=2369) | 70.4 units on a scale | Standard Deviation 22.2 |
| Rheumatoid Arthritis | Hannover Functional Questionnaire (FFbH) Over Time | Month 9 (n=1997) | 71.3 units on a scale | Standard Deviation 22.5 |
| Rheumatoid Arthritis | Hannover Functional Questionnaire (FFbH) Over Time | Month 12 (n=1882) | 71.9 units on a scale | Standard Deviation 22.4 |
| Rheumatoid Arthritis | Hannover Functional Questionnaire (FFbH) Over Time | Month 18 (n=1623) | 72.4 units on a scale | Standard Deviation 22.5 |
| Rheumatoid Arthritis | Hannover Functional Questionnaire (FFbH) Over Time | Month 24 (n=1341) | 72.7 units on a scale | Standard Deviation 22.7 |
Number of Days Missed From Work Due to Rheumatoid Arthritis
Participants reported the number of days they had missed from work in the prior 6 months. The Baseline measurement includes data for the prior 12 months.
Time frame: Baseline and Months 6, 12, 18, and 24
Population: Full analysis set participants who were employed and with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Number of Days Missed From Work Due to Rheumatoid Arthritis | Month 0 (n=1168) | 20.6 days | Standard Deviation 52.4 |
| Rheumatoid Arthritis | Number of Days Missed From Work Due to Rheumatoid Arthritis | Month 6 (n=938) | 9.9 days | Standard Deviation 33.2 |
| Rheumatoid Arthritis | Number of Days Missed From Work Due to Rheumatoid Arthritis | Month 12 (n=728) | 4.4 days | Standard Deviation 21.3 |
| Rheumatoid Arthritis | Number of Days Missed From Work Due to Rheumatoid Arthritis | Month 18 (n=604) | 5.2 days | Standard Deviation 27.1 |
| Rheumatoid Arthritis | Number of Days Missed From Work Due to Rheumatoid Arthritis | Month 24 (n=507) | 3.8 days | Standard Deviation 17.9 |
Participants Assessment of Fatigue Over Time
Participants indicated their level of fatigue over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.
Time frame: Baseline and Month 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Participants Assessment of Fatigue Over Time | Month 0 (n=2940) | 5.8 cm | Standard Deviation 2.5 |
| Rheumatoid Arthritis | Participants Assessment of Fatigue Over Time | Month 3 (n=2727) | 4.5 cm | Standard Deviation 2.7 |
| Rheumatoid Arthritis | Participants Assessment of Fatigue Over Time | Month 6 (n=2351) | 4.2 cm | Standard Deviation 2.6 |
| Rheumatoid Arthritis | Participants Assessment of Fatigue Over Time | Month 9 (n=1976) | 4.0 cm | Standard Deviation 2.6 |
| Rheumatoid Arthritis | Participants Assessment of Fatigue Over Time | Month 12 (n=1864) | 4.0 cm | Standard Deviation 2.6 |
| Rheumatoid Arthritis | Participants Assessment of Fatigue Over Time | Month 18 (n=1608) | 3.9 cm | Standard Deviation 2.6 |
| Rheumatoid Arthritis | Participants Assessment of Fatigue Over Time | Month 24 (n=1335) | 3.7 cm | Standard Deviation 2.6 |
Participants Assessment of Pain Over Time
Participants indicated their level of pain over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Participants Assessment of Pain Over Time | Month 0 (n=2942) | 6.4 cm | Standard Deviation 2.1 |
| Rheumatoid Arthritis | Participants Assessment of Pain Over Time | Month 3 (n=2732) | 4.5 cm | Standard Deviation 2.4 |
| Rheumatoid Arthritis | Participants Assessment of Pain Over Time | Month 6 (n=2356) | 4.2 cm | Standard Deviation 2.4 |
| Rheumatoid Arthritis | Participants Assessment of Pain Over Time | Month 9 (n=1973) | 4.1 cm | Standard Deviation 2.4 |
| Rheumatoid Arthritis | Participants Assessment of Pain Over Time | Month 12 (n=1866) | 3.9 cm | Standard Deviation 2.4 |
| Rheumatoid Arthritis | Participants Assessment of Pain Over Time | Month 18 (n=1609) | 3.9 cm | Standard Deviation 2.4 |
| Rheumatoid Arthritis | Participants Assessment of Pain Over Time | Month 24 (n=1339) | 3.7 cm | Standard Deviation 2.4 |
Patients Global Assessment of Disease Activity Over Time
Participants indicated their global assessment of disease activity over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status.
Time frame: Baseline and Months 3, 6, 9, 12, 18 and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Patients Global Assessment of Disease Activity Over Time | Month 0 (n=2950) | 6.3 cm | Standard Deviation 1.9 |
| Rheumatoid Arthritis | Patients Global Assessment of Disease Activity Over Time | Month 3 (n=2731) | 4.7 cm | Standard Deviation 2.2 |
| Rheumatoid Arthritis | Patients Global Assessment of Disease Activity Over Time | Month 6 (n=2353) | 4.4 cm | Standard Deviation 2.1 |
| Rheumatoid Arthritis | Patients Global Assessment of Disease Activity Over Time | Month 9 (n=1975) | 4.2 cm | Standard Deviation 2.1 |
| Rheumatoid Arthritis | Patients Global Assessment of Disease Activity Over Time | Month 12 (n=1869) | 4.1 cm | Standard Deviation 2.1 |
| Rheumatoid Arthritis | Patients Global Assessment of Disease Activity Over Time | Month 18 (n=1609) | 4.0 cm | Standard Deviation 2.1 |
| Rheumatoid Arthritis | Patients Global Assessment of Disease Activity Over Time | Month 24 (n=1339) | 3.8 cm | Standard Deviation 2.1 |
Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Leflunomide | 22.1 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Non-steroidal anti-inflammatory drug | 46.1 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Hydroxychloroquine/Chloroquine | 2.5 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Other disease-modifying antirheumatic drug | 4.5 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Cyclo-oxygenase 2 (COX-2) Inhibitors | 12.4 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Analgesics | 21.8 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Systemic glucocorticoids | 80.9 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Sulfasalazine | 6.2 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Methotrexate | 54.0 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Analgesics | 15.4 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Other disease-modifying antirheumatic drug | 2.8 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Systemic glucocorticoids | 73.4 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Sulfasalazine | 3.7 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Cyclo-oxygenase 2 (COX-2) Inhibitors | 10.4 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Hydroxychloroquine/Chloroquine | 2.0 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Methotrexate | 52.3 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Non-steroidal anti-inflammatory drug | 36.9 percentage of participants |
| Month 3 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Leflunomide | 18.0 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Non-steroidal anti-inflammatory drug | 34.2 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Other disease-modifying antirheumatic drug | 2.5 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Methotrexate | 53.2 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Sulfasalazine | 3.6 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Analgesics | 14.9 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Cyclo-oxygenase 2 (COX-2) Inhibitors | 10.2 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Leflunomide | 15.9 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Hydroxychloroquine/Chloroquine | 1.6 percentage of participants |
| Month 6 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Systemic glucocorticoids | 69.1 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Analgesics | 14.0 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Methotrexate | 53.1 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Sulfasalazine | 3.2 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Hydroxychloroquine/Chloroquine | 1.2 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Leflunomide | 15.3 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Other disease-modifying antirheumatic drug | 2.3 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Non-steroidal anti-inflammatory drug | 33.9 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Cyclo-oxygenase 2 (COX-2) Inhibitors | 9.6 percentage of participants |
| Month 9 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Systemic glucocorticoids | 65.7 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Cyclo-oxygenase 2 (COX-2) Inhibitors | 9.2 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Leflunomide | 15.0 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Methotrexate | 53.2 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Hydroxychloroquine/Chloroquine | 1.2 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Other disease-modifying antirheumatic drug | 2.0 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Systemic glucocorticoids | 62.1 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Non-steroidal anti-inflammatory drug | 32.7 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Analgesics | 12.9 percentage of participants |
| Month 12 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Sulfasalazine | 3.5 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Sulfasalazine | 3.3 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Leflunomide | 14.1 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Cyclo-oxygenase 2 (COX-2) Inhibitors | 9.6 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Methotrexate | 52.9 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Non-steroidal anti-inflammatory drug | 31.7 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Hydroxychloroquine/Chloroquine | 1.3 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Other disease-modifying antirheumatic drug | 2.2 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Systemic glucocorticoids | 58.8 percentage of participants |
| Month 18 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Analgesics | 11.7 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Sulfasalazine | 2.8 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Analgesics | 12.0 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Hydroxychloroquine/Chloroquine | 1.4 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Non-steroidal anti-inflammatory drug | 30.5 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Leflunomide | 12.7 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Cyclo-oxygenase 2 (COX-2) Inhibitors | 9.7 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Methotrexate | 51.0 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Systemic glucocorticoids | 57.4 percentage of participants |
| Month 24 | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Other disease-modifying antirheumatic drug | 2.1 percentage of participants |
Percentage of Participants With a Significant Therapeutic Response
Significant therapeutic response was determined by DAS28 critical difference (Dcrit). A Dcrit response is a statistically determined value that exceeds the threshold of random fluctuation and signifies a positive individual response during treatment. A DAS28-Dcrit individual therapeutic response is defined as a decrease (improvement) in DAS28 from Baseline of ≥ 1.8. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rheumatoid Arthritis | Percentage of Participants With a Significant Therapeutic Response | Month 3 (n=2620) | 38.9 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With a Significant Therapeutic Response | Month 6 (n=2243) | 49.1 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With a Significant Therapeutic Response | Month 9 (n=1877) | 54.7 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With a Significant Therapeutic Response | Month 12 (n=1776) | 56.3 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With a Significant Therapeutic Response | Month 18 (n=1519) | 60.1 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With a Significant Therapeutic Response | Month 24 (n=1248) | 61.9 percentage of participants |
Percentage of Participants With Impairment in Daily Activities
Participants were asked to report how many days of impairment in daily activities they had experienced in the last 4 weeks.
Time frame: Baseline and Months 3, 6, 9, 18, and 24
Population: Full analysis set with available data at each time point
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rheumatoid Arthritis | Percentage of Participants With Impairment in Daily Activities | No days of impairment | 19.7 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With Impairment in Daily Activities | Less than 7 days of impairment | 28.5 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With Impairment in Daily Activities | 7 to 14 days of impairment | 28.8 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With Impairment in Daily Activities | More than 14 days of impairment | 23.0 percentage of participants |
| Month 3 | Percentage of Participants With Impairment in Daily Activities | 7 to 14 days of impairment | 16.1 percentage of participants |
| Month 3 | Percentage of Participants With Impairment in Daily Activities | Less than 7 days of impairment | 36.3 percentage of participants |
| Month 3 | Percentage of Participants With Impairment in Daily Activities | No days of impairment | 35.8 percentage of participants |
| Month 3 | Percentage of Participants With Impairment in Daily Activities | More than 14 days of impairment | 11.7 percentage of participants |
| Month 6 | Percentage of Participants With Impairment in Daily Activities | More than 14 days of impairment | 9.4 percentage of participants |
| Month 6 | Percentage of Participants With Impairment in Daily Activities | 7 to 14 days of impairment | 14.9 percentage of participants |
| Month 6 | Percentage of Participants With Impairment in Daily Activities | Less than 7 days of impairment | 35.5 percentage of participants |
| Month 6 | Percentage of Participants With Impairment in Daily Activities | No days of impairment | 40.3 percentage of participants |
| Month 9 | Percentage of Participants With Impairment in Daily Activities | No days of impairment | 45.7 percentage of participants |
| Month 9 | Percentage of Participants With Impairment in Daily Activities | More than 14 days of impairment | 7.8 percentage of participants |
| Month 9 | Percentage of Participants With Impairment in Daily Activities | Less than 7 days of impairment | 33.3 percentage of participants |
| Month 9 | Percentage of Participants With Impairment in Daily Activities | 7 to 14 days of impairment | 13.2 percentage of participants |
| Month 12 | Percentage of Participants With Impairment in Daily Activities | 7 to 14 days of impairment | 12.0 percentage of participants |
| Month 12 | Percentage of Participants With Impairment in Daily Activities | More than 14 days of impairment | 6.7 percentage of participants |
| Month 12 | Percentage of Participants With Impairment in Daily Activities | Less than 7 days of impairment | 30.0 percentage of participants |
| Month 12 | Percentage of Participants With Impairment in Daily Activities | No days of impairment | 51.4 percentage of participants |
| Month 18 | Percentage of Participants With Impairment in Daily Activities | Less than 7 days of impairment | 30.4 percentage of participants |
| Month 18 | Percentage of Participants With Impairment in Daily Activities | 7 to 14 days of impairment | 10.8 percentage of participants |
| Month 18 | Percentage of Participants With Impairment in Daily Activities | More than 14 days of impairment | 6.7 percentage of participants |
| Month 18 | Percentage of Participants With Impairment in Daily Activities | No days of impairment | 52.1 percentage of participants |
Percentage of Participants With In-patient Hospitalization
The percentage of participants with in-patient hospitalization in the prior 6 months. Baseline data includes in-patient hospitalizations that occurred within the prior 12 months.
Time frame: Month 6, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rheumatoid Arthritis | Percentage of Participants With In-patient Hospitalization | Baseline (n=2893) | 21.6 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With In-patient Hospitalization | Month 6 (n=2293) | 7.2 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With In-patient Hospitalization | Month 12 (n=1844) | 5.8 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With In-patient Hospitalization | Month 18 (n=1584) | 5.4 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With In-patient Hospitalization | Month 24 (n=1320) | 3.6 percentage of participants |
Percentage of Participants With Low, Moderate and High Disease Activity
The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Low disease activity is defined as a DAS28 score ≤ 3.2; Moderate disease activity as a DAS28 \>3.2 to ≤5.1; High disease activity as a DAS28 \>5.1.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rheumatoid Arthritis | Percentage of Participants With Low, Moderate and High Disease Activity | High disease activity | 64.3 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With Low, Moderate and High Disease Activity | Moderate disease ctivity | 35.7 percentage of participants |
| Rheumatoid Arthritis | Percentage of Participants With Low, Moderate and High Disease Activity | Low disease activity | 0.0 percentage of participants |
| Month 3 | Percentage of Participants With Low, Moderate and High Disease Activity | Moderate disease ctivity | 45.9 percentage of participants |
| Month 3 | Percentage of Participants With Low, Moderate and High Disease Activity | Low disease activity | 30.2 percentage of participants |
| Month 3 | Percentage of Participants With Low, Moderate and High Disease Activity | High disease activity | 23.9 percentage of participants |
| Month 6 | Percentage of Participants With Low, Moderate and High Disease Activity | High disease activity | 17.9 percentage of participants |
| Month 6 | Percentage of Participants With Low, Moderate and High Disease Activity | Low disease activity | 36.5 percentage of participants |
| Month 6 | Percentage of Participants With Low, Moderate and High Disease Activity | Moderate disease ctivity | 45.6 percentage of participants |
| Month 9 | Percentage of Participants With Low, Moderate and High Disease Activity | Moderate disease ctivity | 43.9 percentage of participants |
| Month 9 | Percentage of Participants With Low, Moderate and High Disease Activity | Low disease activity | 41.8 percentage of participants |
| Month 9 | Percentage of Participants With Low, Moderate and High Disease Activity | High disease activity | 14.3 percentage of participants |
| Month 12 | Percentage of Participants With Low, Moderate and High Disease Activity | Moderate disease ctivity | 43.1 percentage of participants |
| Month 12 | Percentage of Participants With Low, Moderate and High Disease Activity | Low disease activity | 43.7 percentage of participants |
| Month 12 | Percentage of Participants With Low, Moderate and High Disease Activity | High disease activity | 13.2 percentage of participants |
| Month 18 | Percentage of Participants With Low, Moderate and High Disease Activity | Low disease activity | 46.7 percentage of participants |
| Month 18 | Percentage of Participants With Low, Moderate and High Disease Activity | High disease activity | 11.6 percentage of participants |
| Month 18 | Percentage of Participants With Low, Moderate and High Disease Activity | Moderate disease ctivity | 41.7 percentage of participants |
| Month 24 | Percentage of Participants With Low, Moderate and High Disease Activity | High disease activity | 10.9 percentage of participants |
| Month 24 | Percentage of Participants With Low, Moderate and High Disease Activity | Moderate disease ctivity | 37.7 percentage of participants |
| Month 24 | Percentage of Participants With Low, Moderate and High Disease Activity | Low disease activity | 51.4 percentage of participants |
Swollen Joint Count (SJC) Over Time
Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Swollen Joint Count (SJC) Over Time | Month 0 (n=2950) | 7.7 swollen joints | Standard Deviation 5.6 |
| Rheumatoid Arthritis | Swollen Joint Count (SJC) Over Time | Month 3 (n=2768) | 3.7 swollen joints | Standard Deviation 4.6 |
| Rheumatoid Arthritis | Swollen Joint Count (SJC) Over Time | Month 6 (n=2375) | 3.0 swollen joints | Standard Deviation 4.1 |
| Rheumatoid Arthritis | Swollen Joint Count (SJC) Over Time | Month 9 (n=2003) | 2.6 swollen joints | Standard Deviation 3.8 |
| Rheumatoid Arthritis | Swollen Joint Count (SJC) Over Time | Month 12 (n=1868) | 2.4 swollen joints | Standard Deviation 3.7 |
| Rheumatoid Arthritis | Swollen Joint Count (SJC) Over Time | Month 24 (n=1326) | 2.0 swollen joints | Standard Deviation 3.4 |
| Rheumatoid Arthritis | Swollen Joint Count (SJC) Over Time | Month 18 (n=1609) | 2.1 swollen joints | Standard Deviation 3.4 |
Tender Joint Count (TJC) Over Time
Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.
Time frame: Baseline and Months 3, 6, 9, 12, 18, and 24
Population: Full analysis set with available data at each time point (indicated by n)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rheumatoid Arthritis | Tender Joint Count (TJC) Over Time | Month 0 (n=2950) | 10.6 tender joints | Standard Deviation 6.7 |
| Rheumatoid Arthritis | Tender Joint Count (TJC) Over Time | Month 3 (n=2778) | 5.4 tender joints | Standard Deviation 6.1 |
| Rheumatoid Arthritis | Tender Joint Count (TJC) Over Time | Month 6 (n=2393) | 4.3 tender joints | Standard Deviation 5.4 |
| Rheumatoid Arthritis | Tender Joint Count (TJC) Over Time | Month 9 (n=2010) | 3.9 tender joints | Standard Deviation 5.4 |
| Rheumatoid Arthritis | Tender Joint Count (TJC) Over Time | Month 12 (n=1886) | 3.6 tender joints | Standard Deviation 5 |
| Rheumatoid Arthritis | Tender Joint Count (TJC) Over Time | Month 18 (n=1621) | 3.4 tender joints | Standard Deviation 4.9 |
| Rheumatoid Arthritis | Tender Joint Count (TJC) Over Time | Month 24 (n=1339) | 3.1 tender joints | Standard Deviation 4.5 |